Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy

• Status: Unknown status
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Cyclooxygenase 2 Inhibitors; Etoricoxib

Criteria

Inclusion Criteria:

• diagnosed with primary hypertrophic osteoarthropathy clinically

• over 16 years old

• no other medication intake

• informed consent signed

Exclusion Criteria:

• below 16 years old

• active gastric ulcer

• inflammatory bowel disease

• New York Heart Association classification（NYHA） II to IV

• liver or renal failure

• allergic to nonsteroid anti-inflammatory drugs

• not willing to participate